Lindor, Keith D.

Small-duct primary sclerosing cholangitis: a long-term follow-up study

Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 213

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

Angulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 203

Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis

Kaya, M., Petersen, B. T., Angulo, P., Baron, T. H., Andrews, J. C., Gostout, C. J., & Lindor, K. D. (2001) · American Journal of Gastroenterology

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 196

In primary sclerosing cholangitis, gallbladder polyps are frequently malignant

Buckles, D. C., Lindor, K. D., LaRusso, N. F., Petrovic, L. M., & Gores, G. J. (2002) · The American Journal of Gastroenterology

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 194

Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system

Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 193

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid: Pilot study: fenofibrate with UDCA for primary biliary cirrhosis

Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 186

Time course of histological progression in primary biliary cirrhosis

Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 184

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression

Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology

Liver Diseases and ImmunityBone health and osteoporosis research

Cited by 180

Long‐term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

Charatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation

Liver Diseases and ImmunityOrgan Transplantation Techniques and Outcomes

Cited by 179

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

Angulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 179

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 178

Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid

Joshi, S., Cauch-Dudek, K., Wanless, I. R., Lindor, K. D., Jorgensen, R., Batts, K., & Heathcote, J. E. (2002) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 174

Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis

Lindor, K. D., Jorgensen, R. A., Therneau, T. M., Malinchoc, M., & Dickson, E. R. (1997) · Mayo Clinic Proceedings

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 166

Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes

Silveira, M. G., Talwalkar, J. A., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 165

Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis

Bangarulingam, S. Y., Gossard, A. A., Petersen, B. T., Ott, B. J., & Lindor, K. D. (2009) · The American Journal of Gastroenterology

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 152

Abnormal hepatic biochemistries in patients with inflammatory bowel disease

Mendes, F. D., Levy, C., Enders, F. B., Loftus, E. V., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 147

Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases

Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2022) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 146

Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo‐controlled trial

Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 142

Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma

Sinakos, E., Saenger, A. K., Keach, J., Kim, W. R., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 142

Natural history of pruritus in primary biliary cirrhosis

Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 141

Diminished survival in asymptomatic primary biliary cirrhosis

Balasubramaniam, K., Grambsch, P. M., Wiesner, R. H., Lindor, K. D., & Dickson, E. R. (1990) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 141

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis

Ali, A. H., Tabibian, J. H., Nasser‐Ghodsi, N., Lennon, R. J., DeLeon, T., Borad, M. J., Hilscher, M., Silveira, M. G., Carey, E. J., & Lindor, K. D. (2018) · Hepatology

Liver Diseases and ImmunityCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 140

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 134